Robert F. Spiera
Director of the Scleroderma, Vasculitis, and Myositis Center · Hospital for Special Surgery
Credentials: · · · ·
History
- Present
Vasculitis · Hospital for Special Surgery
- Present
Scleroderma and Vasculitis Program · Hospital for Special Surgery
- 1992–1995
- 1989–1992
NY Hospital
Research
Rituximab versus cyclophosphamide for ANCA-associated vasculitis
New England Journal of Medicine · 2010 · 2,067 citations
Trial of Tocilizumab in Giant-Cell Arteritis
New England Journal of Medicine · 2017 · 973 citations
Efficacy of remission-induction regimens for ANCA-associated vasculitis
New England Journal of Medicine · 2013 · 570 citations
71 papers
- JS
70 papers
62 papers
56 papers
- GH
48 papers
46 papers
46 papers
44 papers
Clinical trials
- 2026–2030
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Principal investigator · Recruiting · Phase 2, Phase 3
Robert Spiera, MD
- 2019–2026
Principal investigator · Recruiting · Phase 2
Hospital for Special Surgery, New York
- 2017–2020
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Principal investigator · Terminated · Phase 3
Corbus Pharmaceuticals Inc.
- 2015–2017
Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Principal investigator · Terminated · Phase 4
Hospital for Special Surgery, New York